Shares of Altria Group dipped 0.3% to $52.51. The cigarette manufacturer reported earnings of $1.29 a share on revenue of $5.1 billion, in line with FactSet consensus estimates. F

Altria said it may not be able to meet its 2028 business projections for the category due to a “challenging” operating environment, citing unsanctioned rivals. It may also fal

BofA lowered the firm’s price target on Altria Group (MO) to $61 from $65 and keeps a Buy rating on the shares. The firm trimmed its FY25 and

Morgan Stanley lowered the firm’s price target on Altria Group (MO) to $53 from $54 and keeps an Equal Weight rating on the shares. Shares

Altria , the maker of Marlboro cigarettes, has placed under review its 2028 goals for selling alternatives to smoking on the U.S. market, saying on Thursday it may not be able to meet them because of competition from disposable vapes.

Shares of Altria (NYSE: MO), the tobacco giant best known as the domestic maker of Marlboro cigarettes, were heading lower after its guidance for 2025 disappointed investors. Elsewhere, on!, its oral nicotine pouch that competes with Zyn,

Altria Group reported a double beat in Q4, driven by strong growth from its on! brand. Read more to see why I remain bullish on MO stock.

Good day, and welcome to the Altria Group 2024 fourth quarter and full year earnings conference call. [Operator instructions] I would now like to turn the call over to Mac Livingston, vice president of investor relations for Altria Client Services. Please go ahead, sir.

Altria (NYSE:MO) reported earnings on Thursday that beat analyst expectations, but the tobacco giant was hit with a one-two punch on its next-generation products portfolio. Shares of MO ended down 2% for the day as the market also thought its outlook for 2025 was lackluster.

Juul Labs’ Chief Legal Officer says ruling sends a ‘clear message that this freeriding violates U.S. law and American innovation will be

Altria (NYSE:MO) is set to report fourth quarter earnings on Thursday, and investors will focus on the tobacco giant’s portfolio of smoke-free products amid the continued decline of its U.S. cigarette business.

The cigarette giant beat expectations for the fourth quarter by a slender margin, but saw growth in its smoke-free product segments.